Dromotropic
|
WikiDoc Resources for Dromotropic |
|
Articles |
|---|
|
Most recent articles on Dromotropic Most cited articles on Dromotropic |
|
Media |
|
Powerpoint slides on Dromotropic |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Dromotropic at Clinical Trials.gov Clinical Trials on Dromotropic at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Dromotropic
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Dromotropic Discussion groups on Dromotropic Patient Handouts on Dromotropic Directions to Hospitals Treating Dromotropic Risk calculators and risk factors for Dromotropic
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Dromotropic |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
A dromotropic agent is one which affects the conduction velocity of the AV node, and subsequently the rate of electrical impulses in the heart.[1][2]
Agents that are dromotropic are often (but not always) inotropic and chronotropic. For example, parasympathetic stimulation is usually negatively dromotropic, inotropic, and chronotropic.
Non-dihydropyridine calcium channel blockers such as verapamil block the slow inward calcium current in cardiac tissues thereby having a negatively dromotropic, chronotropic and inotropic effect[3]. This (and other) pharmacological effect makes these drugs useful in the treatment of angina pectoris. Conversely, they can lead to symptomatic disturbances in cardiac conduction and bradyarrhythmias, and may aggravate left ventricular failure[4].